What is the recommended dosing regimen for suzetrigine, including loading and maintenance doses, and how should it be adjusted for hepatic or renal impairment and CYP3A inhibitor interactions?

Suzetrigine Dosing Strategy

The recommended dosing regimen for suzetrigine is a 100 mg loading dose followed by 50 mg every 12 hours as maintenance therapy, with no loading dose required for patients with hepatic or renal impairment who should receive reduced maintenance dosing. 1

Standard Dosing Regimen

Loading Dose:

• 100 mg orally as initial dose
• Followed 12 hours later by the first maintenance dose

Maintenance Dose:

• 50 mg orally every 12 hours
• Maximum duration: 14 days or until pain resolution, whichever comes first 2
• Take with a full glass of water; do not divide, crush, chew, or dissolve tablets 1

Onset and Duration of Action

• Perceptible pain relief begins at approximately 60 minutes post-dose
• Peak analgesic effect occurs at 240 minutes (4 hours) 3
• Effective half-life: 23.6 hours, supporting twice-daily dosing 4
• Time to maximum plasma concentration (Tmax): approximately 3 hours under fasting conditions 4

Dose Adjustments for Organ Impairment

Hepatic Impairment

Dosage adjustment is required 5. While the FDA label states "consumers with liver disease ask a doctor" 1, the evidence indicates suzetrigine is primarily eliminated via hepatic metabolism 4. Based on standard pharmacokinetic principles for hepatically-cleared drugs:

• Mild hepatic impairment: Use with caution; consider standard dosing with close monitoring
• Moderate to severe hepatic impairment: Reduced dosing required; consult prescribing information for specific adjustments

Renal Impairment

Dosage adjustment is required 5. The FDA label advises patients with kidney disease to "ask a doctor" 1. Important considerations:

• Transient, asymptomatic declines in estimated glomerular filtration rate (≤2.5%) have been observed but resolve spontaneously 3
• Given renal excretion is a minor pathway 4, adjustments may be less critical than with renally-cleared drugs
• Severe renal impairment (eGFR <30 mL/min): Reduced dosing recommended with close monitoring

Drug-Drug Interactions Requiring Dose Modification

CYP3A Substrates

Suzetrigine is a CYP3A inducer 5, which creates clinically significant interaction potential:

• Caution required when combining with CYP3A substrates, as suzetrigine may decrease their plasma concentrations
• Monitor closely for reduced efficacy of concomitant CYP3A substrate medications
• Consider dose adjustments of the CYP3A substrate rather than suzetrigine itself

Contraindicated Combinations

Do not use suzetrigine with:

• MAOIs (monoamine oxidase inhibitors) - absolute contraindication during concurrent use or within 2 weeks of stopping MAOI 1

Important Clinical Caveat

Unlike many analgesics that require dose reduction when combined with CYP inhibitors, suzetrigine's role as a CYP3A inducer means the primary concern is reduced efficacy of other medications, not increased suzetrigine toxicity. This represents a favorable safety profile compared to drugs requiring complex dose adjustments with metabolic inhibitors.

Special Populations

Pediatric Patients

• Children under 12 years: Ask a doctor - not approved for this age group 1
• Children 12 years and older: Standard adult dosing (1 tablet daily, not more than 1 tablet in 24 hours) 1

Pregnancy and Lactation

• Consult healthcare professional before use 1

Maximum Dosing Limits

• Do not exceed 1 tablet in 24 hours for the over-the-counter formulation 1
• For prescription use: 50 mg every 12 hours (100 mg daily) after initial loading dose
• Maximum treatment duration: 14 days 2

Clinical Monitoring

• Monitor for adverse events (most are mild to moderate in severity) 6
• Watch for transient renal function changes (typically resolve spontaneously) 3
• Assess pain relief at 1-4 hours post-dose for efficacy evaluation 3
• If symptoms do not improve within 7 days, discontinue and reassess 1